Kidney disease often creeps in silently, and many patients aren’t diagnosed until major damage is already done. New research ...
Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...
Chronic kidney disease (CKD) affects nearly 36 million people. “CKD is a real public health crisis, and one that’s steadily rising,” said Merlin Thomas, M.B.Ch.B., Ph.D., FRACP, a professor of ...
Phase 3 trials showed Vanrafia slowed the decline in kidney function for adults with the progressive autoimmune kidney ...
Early kidney damage is silent but preventable routine blood and urine tests catch it before symptoms.
Kidney aging rarely draws attention until something goes wrong. Over time, these organs quietly lose strength, filter less efficiently, and struggle to keep the body balanced.
Advancing chronic kidney disease may raise risk of cognitive decline, with attention, memory and brain function impacted, new JAMA study reveals.
Aims Heart failure (HF) often coexists with chronic kidney disease (CKD), impacting prognosis. This study aims to evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results